Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Philogen reports €230 million net profit and strong liquidity for 2025

Philogen reported a net profit of about €230 million for 2025 and cash and cash equivalents of €380 million. Management approved a dividend of €0.70 per share and proposed a share buyback program of up to 35% of share capital. The product pipeline (including Nidlegy and Fibromun) showed clinical progress, and strategic partnerships such as the OncoACP3 deal are expected to support revenue growth. For 2026 Philogen plans moderate spending of €4–5 million per month and emphasizes financial discipline despite regulatory and clinical risks. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Philogen Spa has already paid €0.70 in dividends. The last payout was in May.

Financials

In the last quarter, Philogen Spa had revenue of €2.03m and net profit of -€9.8m

(EUR)	June 2026	YoY
Revenue	2.03m	53.38%
Gross profit	-5.43m	102.03%
Net profit	-9.8m	31.54%
EBITDA	-10.66m	53.77%

Fundamentals

Metric	Value
Market capitalization	€610.81m
Number of shares	28.88m
52-week high/low	€26.00 - €19.56
Dividend yield	3.34%
Dividends TTM	€0.70
Beta	-0.02
P/E ratio	3.80
PEG ratio	0.01
P/B ratio	2.55
P/S ratio	1.94

Company profile

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.